Table 1.
Features | Bedi 1994 | Behera 1994 | Kumar 2000 | Kumar and Gaur 2000 | Chakrabarti 2002 | Shah 2003 | Agarwal 2006 | Our study 2007 |
---|---|---|---|---|---|---|---|---|
Total | 20 | 35 | 29 | 32 | 89 | 113 | 126 | 42 |
Mean age (years) | NA | 34.3 | 36.3 | 34 | 36.4 | 32 | 34.4 | 31.2 |
Mean duration of asthma (years) | NA | 11.1 | 12.5 | 12 | 12.1 | 11 | 8.8 | 12.2 |
History of asthma (%) | 100 | 94 | 100 | 100 | 90 | 99 | 100 | 100 |
Expectoration of sputum plugs (%) | 55 | NA | 34.4 | 31 | 69 | 37 | 47.6 | 38.1 |
Peripheral eosinophilia (%) | 100 | 43 | 100 | 100 | 100 | 83 | NA | 100 |
Fleeting shadows (%) | 85 | 77 | 28 | 69 | 74 | 89 | 36.5 | 66.7 |
Skin test to Aspergillus | ||||||||
Type I (%) | 100 | 80 | 100 | 100 | 82 | 100 | 100 | 97.6 |
Type III (%) | 35 | 29 | 44.8 | 53 | 26 | 100 | 75.4 | 69.1 |
Elevated total IgE | NA | NA | 100 | 100 | NA | 100 | NA | 100 |
Aspergillus-specific IgE/IgG | NA | NA | 100 | 100 | NA | 96 | NA | 81 |
Serum precipitins against Aspergillus (%) | 100 | 77 | 79 | 75 | 72 | 85 | NA | 100 |
Central bronchiectasis (%) | NA | 71 | 83 | 77 | 69 | 99 | 73.1 | 100 |
History of anti tuberculous drugs (%) | NA | 34 | NA | NA | 29 | 81 | 46.8 | 91 |
NA: Not available